New breast cancer (BC) diagnoses will soon reach 2.5–3 million/year worldwide, with 15–25% of them being triple-negative breast cancer (TNBC), the most aggressive type, characterized for lacking the main pharmacological targets: estrogen and progesterone receptors (ERs and PRs), as well as HER2 overexpression. Here, PGR is linked to breast cancer.